Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1Leukemia 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Temozolomide 62Cyclophosphamide 60Radiotherapy 48Doxorubicin 36Filgrastim 26Radiation 24Irinotecan 24fludarabine 23Gemcitabine 23Magnetic Resonance Spectroscopy 21Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Antibodies, Monoclonal × Sarcoma × Clear all
NCT00077493 2007-12-28

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

MedImmune LLC

Phase 1 Suspended
95 enrolled
LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡